Appointment to board at Synergy
This article was originally published in Scrip
Synergy Pharmaceuticals (US), a biopharmaceutical company focused on developing drugs to treat gastrointestinal disorders and diseases, has named Dr Melvin Spigelman as a director. In addition, he has been appointed chairman of the company's clinical oversight committee, as well as a member of the compensation committee. Dr Spigelman has served as director of R&D for the Global Alliance for TB Drug Development since June 2003.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.